The use of androgen antagonists such as proxalutamide is able to alter SREBP-1/FASN/lipogenesis and androgen signal axis and subsequently decrease LD biogenesis and constitutes a promising approach to decrease prostate cancer cell proliferation and invasion [80] Very interestingly, transcriptional factor peroxisome proliferator-activated receptor gamma (PPARγ) was able to interact with kinase tether histone-lysine N-methyltransferase 2D (KMT2D) to affect lipid synthesis and subsequently LDs (Figure 2) [81]. Here, KMT2D is linked to prostate cancer.